Voyager Therapeutics Price to Sales Ratio 2014-2022 | VYGR

Historical PS ratio values for Voyager Therapeutics (VYGR) over the last 10 years. The current P/S ratio for Voyager Therapeutics as of July 01, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Voyager Therapeutics P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-07-01 6.08 7.26
2022-03-31 7.62 $0.84 9.09
2021-12-31 2.71 $0.99 2.73
2021-09-30 2.63 $0.42 6.21
2021-06-30 4.13 $3.51 1.18
2021-03-31 4.71 $4.25 1.11
2020-12-31 7.15 $4.57 1.57
2020-09-30 10.67 $5.30 2.01
2020-06-30 12.62 $2.73 4.62
2020-03-31 9.15 $3.17 2.89
2019-12-31 13.95 $2.84 4.92
2019-09-30 17.21 $1.99 8.65
2019-06-30 27.22 $1.50 18.17
2019-03-31 19.14 $0.36 52.58
2018-12-31 9.40 $0.24 39.52
2018-09-30 18.92 $0.41 45.92
2018-06-30 19.54 $0.39 50.00
2018-03-31 18.79 $0.36 52.83
2017-12-31 16.60 $0.38 43.37
2017-09-30 20.59 $0.24 86.02
2017-06-30 8.96 $0.33 27.50
2017-03-31 13.24 $0.43 30.94
2016-12-31 12.74 $0.56 22.60
2016-09-30 12.01 $1.65 7.29
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.234B $0.037B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00